The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | ctDNA clearance and outcomes in the INTERCEPT colorectal cancer study
Emerik Osterlund, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from the INTERCEPT study evaluating circulating tumor DNA (ctDNA) dynamics after curative-intent procedures in colorectal cancer. The analysis assessed ctDNA clearance patterns using tumor-informed minimal residual disease assays and their correlation with disease-free survival. Results showed that while adjuvant therapy can induce ctDNA clearance in some patients, spontaneous and durable clearance is rare. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Here we present the subgroup from the Intercept trial looking at ctDNA biology after curative-intent procedures. So either a surgery or local ablative therapy and then also adjuvant therapy if that was indicated. And all these surgeries were performed as routine care and adjuvant as well and then ctDNA was followed after surgery and then every three months and sort of the main finding here was that spontaneous clearances were seen in four percent of the patients that were ever ctDNA positive after the surgery and these were durable in roughly half of them so that they were negative on two or more subsequent tests and almost all of those had no recurrences during follow-up and kind of these patients that cleared their ctDNA also had a better disease-free survival (DFS) than the others that did not clear it...
Here we present the subgroup from the Intercept trial looking at ctDNA biology after curative-intent procedures. So either a surgery or local ablative therapy and then also adjuvant therapy if that was indicated. And all these surgeries were performed as routine care and adjuvant as well and then ctDNA was followed after surgery and then every three months and sort of the main finding here was that spontaneous clearances were seen in four percent of the patients that were ever ctDNA positive after the surgery and these were durable in roughly half of them so that they were negative on two or more subsequent tests and almost all of those had no recurrences during follow-up and kind of these patients that cleared their ctDNA also had a better disease-free survival (DFS) than the others that did not clear it.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
